Which antibiotic wins for skin infections? study pits doxycycline against TMP-SMX

NCT ID NCT03637400

Completed Disease control Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two common antibiotics, doxycycline and TMP-SMX, for treating uncomplicated skin infections like boils and cellulitis. 269 people aged 9 to 85 took one of the drugs for 7 days. Researchers checked if the infection cleared up early, at the end of treatment, and one month later.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: doxycycline and trimethoprim/sulfamethoxazole (TMP-SMX)
What this could lead to: If one antibiotic works better, it could help doctors choose the best treatment for common skin infections, reducing complications.
What could go wrong: This is a Phase 2 study with 269 people, so results may not apply to everyone. Both drugs have side effects like nausea or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cellulitis methicillin-resistant staphylococcus aureus infectious disease skin infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS SKIN INFECTION

Contacts and locations

Locations

Harbor-UCLA Medical Center

Torrance, California, 90509, United States
Olive View-UCLA Medical Center

Sylmar, California, 91342, United States
Washington University

St Louis, Missouri, 63130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.